Essais liés11clinical trials
VilleLa Jollalocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT03742037

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
ZL-1310 Cancer Phase 3 NCT07218146 A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) RECRUITING
BHV-7000 Épilepsie Phase 2/3 NCT06132893 RISE 2 — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy RECRUITING
AIDP — Automated Imaging Differentiation of Parkinsonism Parkinson À vérifier NCT05913687 AIDP — Automated Imaging Differentiation of Parkinsonism ACTIVE_NOT_RECRUITING
VHB937 Sclérose latérale amyotrophique Phase 2 NCT06643481 ASTRALS — A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS) ACTIVE_NOT_RECRUITING
Ianalumab Lupus Phase 3 NCT05639114 Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) ACTIVE_NOT_RECRUITING
Cenerimod 0.5 mg Lupus Phase 2 NCT03742037 Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus COMPLETED
ION363 Sclérose latérale amyotrophique Phase 3 NCT04768972 FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) ACTIVE_NOT_RECRUITING
Cromolyn Sodium (34.2 mg BID) Sclérose latérale amyotrophique Phase 2 NCT07142291 PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS RECRUITING
ASSESS ALL ALS Study Sclérose latérale amyotrophique À vérifier NCT06578195 ASSESS ALL ALS Study RECRUITING
PREVENT ALL ALS Study Sclérose latérale amyotrophique À vérifier NCT06581861 PREVENT ALL ALS Study RECRUITING
DYNE-251 Myopathies Phase 1/2 NCT05524883 DELIVER — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping ACTIVE_NOT_RECRUITING